{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000029","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.529990+00:00","generated_at":"2026-05-24T06:42:57.827715+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Serina Therapeutics posts FY 2024 net loss of $11.1M vs net income of $5.3M in 2023","bullets":["Revenues fell to $56K from $3.2M; operating expenses rose to $17.1M from $6.3M.","Cash and equivalents $3.7M at Dec 31, 2024; plus $5M from JuvVentures in Jan 2025, projected to fund through Q2 2025.","R&D expense increased $5.1M to $7.5M, driven by SER-252 development and higher headcount.","Sold UniverXome subsidiary in Dec 2024, eliminating $11.2M debt; $10M equity financing from JuvVentures secured.","Appointed Karen J. Wilson and Dr. Jay Venkatesan to board; targeting first patient in Phase 1b trial for SER-252 in Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000029","json":"https://secwatch.observer/filing/0001708599-25-000029.json","markdown":"https://secwatch.observer/filing/0001708599-25-000029.md","text":"https://secwatch.observer/filing/0001708599-25-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000029/0001708599-25-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000029/ser-20250324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:42:57.827715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}